- Home
- EWCZ vs ENGN Comparison
EWCZ vs ENGN Comparison
Compare EWCZ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- ENGN
- Stock Information
- Founded
- EWCZ 2004
- ENGN 1999
- Country
- EWCZ United States
- ENGN Canada
- Employees
- EWCZ N/A
- ENGN N/A
- Industry
- EWCZ Package Goods/Cosmetics
- ENGN
- Sector
- EWCZ Consumer Discretionary
- ENGN
- Exchange
- EWCZ Nasdaq
- ENGN Nasdaq
- Market Cap
- EWCZ 146.9M
- ENGN 297.7M
- IPO Year
- EWCZ 2021
- ENGN N/A
- Fundamental
- Price
- EWCZ $3.60
- ENGN $3.39
- Analyst Decision
- EWCZ Buy
- ENGN Buy
- Analyst Count
- EWCZ 7
- ENGN 7
- Target Price
- EWCZ $5.64
- ENGN $23.29
- AVG Volume (30 Days)
- EWCZ 753.6K
- ENGN 54.9K
- Earning Date
- EWCZ 05-14-2025
- ENGN 06-13-2025
- Dividend Yield
- EWCZ N/A
- ENGN N/A
- EPS Growth
- EWCZ 29.60
- ENGN N/A
- EPS
- EWCZ 0.22
- ENGN N/A
- Revenue
- EWCZ $216,916,000.00
- ENGN N/A
- Revenue This Year
- EWCZ N/A
- ENGN N/A
- Revenue Next Year
- EWCZ $2.69
- ENGN N/A
- P/E Ratio
- EWCZ $16.23
- ENGN N/A
- Revenue Growth
- EWCZ N/A
- ENGN N/A
- 52 Week Low
- EWCZ $2.72
- ENGN $3.27
- 52 Week High
- EWCZ $12.05
- ENGN $14.67
- Technical
- Relative Strength Index (RSI)
- EWCZ 51.78
- ENGN 27.30
- Support Level
- EWCZ $3.12
- ENGN $3.51
- Resistance Level
- EWCZ $3.42
- ENGN $3.99
- Average True Range (ATR)
- EWCZ 0.21
- ENGN 0.40
- MACD
- EWCZ 0.10
- ENGN -0.00
- Stochastic Oscillator
- EWCZ 98.48
- ENGN 10.71
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.